source
- AbbVie says Skyrizi maintains strong sales momentum as competition risesAbbVie highlighted that its immunology drug Skyrizi continues to generate robust sales despite increasing competition in the market. The company noted that demand for the therapy remains solid and…
- Pharma groups support revised 340B rebate pilot that permits limited rebate denialsHealth Resources and Services Administration (HRSA) announced details of a revised 340B rebate pilot. The new rules would let drug manufacturers refuse rebates on a limited set of drugs, a shift fr…